ORAL COMMUNICATION | Semaglutide Plus Empagliflozin Improves Renal Outcomes Compared With Monotherapies in Type 2 Diabetes: A Real-World Study. Ital J Med 2026, 20 (s1). https://doi.org/10.4081/.